Patent · US Active

Methods of administering a composition comprising a Tn3 scaffold and a CD40L-specific monomer

US11555062B2 · kind B2 · utility

0Cited by

27References

39Claims

0Family size

Assignee

Viela Bio, Inc. · US

Inventors

Anthony Coyle · Washington, US
Manuel Baca · Gaithersburg, US
Thomas Thisted · New Market, US
Stacey Drabic · Gaithersburg, US
Luba Grinberg · Gaithersburg, US
Shabazz Novarra · Gaithersburg, US
Vaheh Oganesyan · Gaithersburg, US
Ronald Herbst · Gaithersburg, US
David Kenneth Spencer · Gaithersburg, US

Key dates

Filing date	Jul 28, 2021
Grant date	Jan 17, 2023
Priority date	—
Expiry date	Jul 28, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/31
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.